Image Place holder

Michael R. Shafique, MD


Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Shafique earned his MD degree at the University of Virginia, School of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center and, most recently, a Hematology and Oncology Fellowship at University of South Florida/Moffitt Cancer Center. Dr. Shafique devotes the majority of clinical time treating lung cancer. However, he will also cares for patients with a wide spectrum of diagnoses as part of early phase clinical trials.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of South Florida - Hematology and Oncology

Residency:

  • Duke University Medical Center - Internal Medicine

Medical School:

  • University of Virginia School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19293
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Condition:
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition:
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AMP-514 (Durvalumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); CP-675,206 (tremelimumab); Dexamethasone; Durvalumab; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel; tremelimumab
Open

CLINICAL TRIAL 18999
Early Detection of Cancer Progression: Leveraging Team Science
Condition:
Intervention:
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition:
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Condition:
Intervention: Poziotinib
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 19344
A Phase 1/2 Trial of CV301 in Combination with Anti-PD-1 Therapy versus Anti-PD-1 Therapy alone in Subjects with Non-Small Cell Lung Cancer
Condition:
Intervention: FPV-CV301; MVA-BN-CV301; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19339
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Condition:
Intervention: AZD9291 (Osimertinib); Avastin (Bevacizumab); Bevacizumab
Open

CLINICAL TRIAL 19077
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Condition:
Intervention: Paraplatin (carboplatin); carboplatin; cisplatin; etoposide
Open

CLINICAL TRIAL 19497
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Condition:
Intervention: MLN4924 (Pevonedistat); Paraplatin (carboplatin); Pevonedistat; Taxol (paclitaxel); Taxotere (docetaxel); carboplatin; docetaxel; paclitaxel
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May;10:931-940. Pubmedid: 29760563. Pmcid: PMC5937504.
  • Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun;19(8):39. Pubmedid: 29931587.
  • Shafique MR, Lee MC, Han HS. Treatment of the Pregnant Patient with Breast Cancer. South Med J. 2017 Oct;110(10):627-631. Pubmedid: 28973702.
  • Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A. Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization. Surg Infect (Larchmt). 2014 Jun;15(3):182-186. Pubmedid: 24773230. Pmcid: PMC4696441.
  • Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Tr. 2014 Feb;20(2):257-263. Pubmedid: 24269380. Pmcid: PMC4140655.